Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM)
Active, not recruiting
- Conditions
- Myeloproliferative Disorders
- Registration Number
- NCT06481345
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
Retrospective study assessing the impact of IDH1/2, SRSF2 or SF3B1 mutations on event free survival of MPN patients
- Detailed Description
Patients with a diagnosis of MPN and a mutation of IDH1/2, SRSF2 or SF3B1 will be included. Clinical and biological characterisation at diagnosis, as well as evlution will be recorded. Event free survival will be assessed in each group (event = thrombosis, transformation to mylofibrosis/acute leukemia, death).
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Patients with MPN diagnosis
- Mutation in IDH1/2, SRSF2 or SF3B1
Exclusion Criteria
- Unable to consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Event free survival 3 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link IDH1/2, SRSF2, or SF3B1 mutations to myeloproliferative neoplasia progression?
How do IDH1/2, SRSF2, or SF3B1 mutations affect event-free survival in MPN patients compared to standard-of-care outcomes?
Which biomarkers correlate with thrombosis or leukemic transformation in MPN patients with IDH/SRSF2/SF3B1 mutations?
What adverse events are associated with IDH1/2, SRSF2, or SF3B1 mutation-driven MPN and how are they managed?
Are there combination therapies targeting IDH1/2, SRSF2, or SF3B1 mutations in MPN being developed by pharmaceutical companies?
Trial Locations
- Locations (1)
Chu Brest
🇫🇷Brest, France